Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis